Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 5Hematologic Neoplasms 2Cardiotoxicity 2Sarcoma 1Prostatic Neoplasms 1Lymphoma 1Heart Failure 1Cardiovascular Abnormalities 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 41fludarabine 35Tacrolimus 28Mycophenolic Acid 27Whole-Body Irradiation 25Busulfan 24fludarabine phosphate 21Melphalan 19thymoglobulin 16Antilymphocyte Serum 16Methotrexate 13Thiotepa 12Stem Cell Transplantation 9Rituximab 9Granulocyte Colony-Stimulating Factor 9Filgrastim 8Cyclosporine 8trametinib 7Sirolimus 7Nivolumab 5ruxolitinib 4merphos 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Bendamustine Hydrochloride 4tocilizumab 3itacitinib 3fedratinib 3dabrafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Neoplasms × Carvedilol × Clear all
NCT02717507 2025-04-23

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Children's Oncology Group

Phase 2 Completed
196 enrolled 26 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT04190433 2023-05-24

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Mayo Clinic

Phase 2 Withdrawn
BreastLymphoidOther hematologic neoplasmSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡